Novel method for preparing Scn1a < + / -> model mouse by using Cre-loxP system

The genetic background of Scn1a+/- model mice was optimized through the Cre-loxP system, and the problems of unclear genetic background and poor genetic stability in the prior art were solved, and efficient preparation of Scn1a+/- model mice and Dravet syndrome disease model were achieved. The effective verification of the drug development process has promoted the process of drug development.

CN118947634AActive Publication Date: 2024-11-15SHENZHEN QINYE PHARM TECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411382524.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-11-15
Estimated Expiration
2044-09-30

AI Technical Summary

Technical Problem

The existing Scn1a+/- model mice have unclear genetic background, poor genetic stability, low survival rate, and insufficient phenotype judgment before and after drug treatment, making it difficult to effectively use in the study of Dravet syndrome disease model.

Method used

Using the Cre-loxP system, the genetic background of Scn1a+/- model mice was gradually optimized through a series of hybridization steps, ensuring that the ratio of 50% C57/50%129 was close, complex crossing was replenished to improve genetic stability, and through the heat-induced seizure test Verify the phenotypic differences in model mice.

Benefits of technology

The obtained Scn1a+/- model mice have obvious clear genetic background, high genetic stability, and no trait separation. They can quickly promote the development speed of anti-Dravet syndrome drugs, significantly improving the survival rate and feasibility of experimental operations in model mice. sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118947634A_ABST
    Figure CN118947634A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of cranial nerve animal models, in particular to a method for preparing an Scn1a < + / -> model mouse by using a Cre-loxP system (as shown in figure 1). A 100% C57 background Scn1aflox / flox mouse and a wild type 100% 129 background mouse are hybridized to obtain an F1 generation Scn1aflox / + mouse of which the background theoretical value is 50% C57 / 50% 129. The Scn1aflox / + mouse is repeatedly hybridized with the wild type 100% 129 background mouse for three rounds, and then the F4 generation Scn1aflox / + mouse with the background theoretical value of 6.25% C57 / 93.75% 129 is obtained. The F4 generation Scn1aflox / + mouse with the background theoretical value of 6.25% C57 / 93.75% 129 is hybridized with the 100% C57 background Cre mouse, and an Scn1a + / -model mouse with the background close to 50% C57 / 50% 129 (as shown in Figure 4) is obtained. The 50% C57 / 50% 129 Scn1a < + / -> model mouse prepared by the method has the advantages of clear gene background, stable heredity, no character separation, easiness in experimental operation and the like, and particularly, the 50% C57 / 50% 129 Scn1a < + / -> model mouse (as shown in Figure 5) can be obtained on a large scale in the same period. Compared with a wild type mouse, the model mouse has obvious phenotypic difference, so that the research and development speed of the anti-Dravot syndrome medicine can be quickly promoted.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of brain nerve animal models, and specifically to a method for preparing Scn1a by using the Cre-loxP system. + / - A method for preparing a model mouse, wherein the model mouse can be used as a disease model of Dravet syndrome. Background Art

[0002] Voltage-gated sodium channel (VGSC) is composed of α subunits and multiple auxiliary β subunits, allowing sodium ions to pass through the cell membrane, allowing excitable cells to generate and conduct action potentials. Currently, 9 α subunits of VGSC have been identified, namely voltage-gated sodium channel α1 to 9 subunits (Nav1.1 to Nav1.9). The sodium channel α1 subunit (Sodium ChannelNav1.1, SCN1A) gene encodes Nav1.1, and its pathogenic variants can cause epileptic seizures by affecting the function of sodium channels. The SCN1A gene is located on chromosome 2q24.3 and contains 26 exons. The encoded Nav1.1 is a tertiary structure formed by a transmembrane mosaic of a peptide chain containing 2009 amino acids. The disease caused by its variant is autosomal dominant. Nav1.1 is composed of 4 homologous transmembrane domains (DⅠ~DⅣ), each of which includes 6 interconnected transmembrane α helical segments (S1~S6). The connecting segment between the 5th helix (S5) and the 6th helix (S6) is loop-shaped, called the pore loop (P loop), which enters the membrane from the outside of the cell membrane and together with the S5 and S6 transmembrane helical segments constitutes the selective pore of the sodium ion channel. The 4th helical segment (S4) of each domain contains positively charged amino acid residues that can sense changes in cell membrane potential and is the voltage receptor of the sodium channel. In the central nervous system, Nav1.1 is mainly expressed in the cell body and dendrites, and can also be expressed in the axon initial segment of some interneurons. It plays a very important role in the generation and propagation of action potentials and is related to the development of the nervous system. More than 1,900 types of SCN1A gene mutations have been discovered (human gene mutation database 2020.3). The epilepsy phenotypes caused by pathogenic variants of the SCN1A gene range from genetic epilepsy with febrile seizures plus (GEFS+) in mild cases to Dravet syndrome (DS) or SCN1A gene-related early-onset developmental and epileptic encephalopathies (DEEs) in severe cases. They also include myoclonic-atonicepilepsy (MAE), epilepsy with migrating focal seizures (EIMFS), and early-onset benign childhood occipital epilepsy syndrome (Panayiotopoulos syndrome).

[0003] Homozygous Scn1a - / - Model mice, embryonic lethal. Simple C57 background mice as Scn1a + / - Model mice are prone to lethality. Simple 129 background mice are used as Scn1a + / - The phenotypic differences of model mice are not obvious enough to make effective judgments before and after drug treatment. + / - The modeling method is to use the Cre-loxP system to prepare the C57 background Scn1a flox / flox (Mouse sperm with the same-direction crossover (x) P1 sites [Locus of crossover (x) P1, Loxp] added to both sides of exon 26 of the mouse Scn1a gene was fused with wild-type mouse oocytes on the 129 background, and the fertilized eggs were injected with cyclization recombinase (Cre) mRNA. After the edited fertilized eggs were transplanted into surrogate mice, 50% C57 / 50% 129 Scn1a of the F0 generation was obtained. + / - Model mice (such as Figure 2 ), the F0 generation is self-fertilized, and the F1 generation mice obtained are genetically unstable, the genes will be offset, the background is unclear, the phenotypes of model mice vary greatly between species, and the survival rate is low. It takes 2-3 generations to be stable (such as Figure 3 ). Summary of the invention

[0004] The present invention aims to provide a method for preparing Scn1a using the Cre-loxP system. + / - The invention provides a method for model mice to solve the problems raised in the above background technology.

[0005] To achieve the above object, the present invention provides the following technical solution: a method for preparing Scn1a using the Cre-loxP system + / - The method of the model mouse comprises the following steps:

[0006] S1: Scn1a with 100% C57 background flox / flox (LoxP sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, resulting in a homozygous loxP mouse) The mouse was hybridized with a wild-type 100% 129 background mouse to obtain an F1 generation with a theoretical background value of 50% C57 / 50% 129 Scn1a flox / + Mice;

[0007] S2: On this basis, the theoretical background value of the F1 generation is 50% C57 / 50% 129 Scn1a flox / +The mice were crossed with wild-type 100% 129 mice to obtain an F2 generation with a theoretical background value of 25% C57 / 75% 129 Scn1a flox / + Mice;

[0008] S3: On this basis, the theoretical background value of the F2 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain an F3 generation with a theoretical background value of 12.5% ​​C57 / 87.5% 129 Scn1a flox / + Mice;

[0009] S4: On this basis, the theoretical background value of the F3 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain the F4 generation with a theoretical background value of 6.25% C57 / 93.75% 129 Scn1a flox / + Mice;

[0010] S5:Scn1a flox / + Mice were repeatedly crossed with wild-type 100% 129 mice for ≥3 rounds;

[0011] S6: Scn1a flox / + The mice were repeatedly crossed with wild-type 100% 129 mice. After 3 rounds of crosses, the theoretical background value of the F4 generation was 6.25% C57 / 93.75% 129 Scn1a flox / + The mice were crossed with Cre mice with a 100% C57 background to obtain Scn1a with a background close to 50% C57 / 50% 129 flox / + Model mice.

[0012] Preferably, the S1 contains 100% C57 background Scn1a flox / flox The mouse has loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene, and is a mouse containing homozygous loxP.

[0013] Preferably, Scn1a in the S1 flox / + The (50% C57 / 50% 129) mouse is a mouse containing heterozygous loxP by adding loxP sites in the same direction on both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background is 50% C57 / 50% 129.

[0014] Preferably, Scn1a in S3 flox / +The (25%C57 / 75%129) mouse is a mouse containing heterozygous loxP by adding loxP sites in the same direction on both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background is 25%C57 / 75%129.

[0015] Preferably, Scn1a in S3 flox / + The (12.5%C57 / 87.5%129) mouse is a mouse containing heterozygous loxP with loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene. The mouse genotype background is 12.5%C57 / 87.5%129.

[0016] Preferably, Scn1a in S6 flox / + The (6.25%C57 / 93.75%129) mouse is a mouse containing heterozygous loxP with loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene. The mouse genotype background is 6.25%C57 / 93.75%129.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The 50% C57 / 50% 129 Scn1a prepared by this method + / - The model mice have the advantages of clear genetic background, genetic stability, non-separation of traits, and easy experimental operation, especially in the same period, 50% C57 / 50% 129 Scn1a can be obtained in large quantities + / - Model mice. This model mouse has obvious phenotypic differences compared to wild-type mice, so it can quickly advance the development of anti-Dravet syndrome drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative labor.

[0020] Figure 1 Scn1a + / - Schematic diagram of the mouse model building experiment;

[0021] Figure 2 Scn1a + / - Flowchart of mouse model establishment;

[0022] Figure 3 Scn1a + / - Mouse model phenotypic differences diagram;

[0023] Figure 4 The Scn1a of the present invention + / - Flowchart for mouse model establishment;

[0024] Figure 5 The Scn1a of the present invention + / - Mouse model mouse phenotypic stability diagram;

[0025] Figure 6 The Scn1a of the present invention flox / + Schematic diagram of mouse genotyping;

[0026] Figure 7 The Scn1a of the present invention flox / + Figure 1. Results of mouse genotype identification experiment.

[0027] Figure 8 The Scn1a of the present invention + / - Schematic diagram of genotyping of model mice;

[0028] Fig. 9 The Scn1a of the present invention + / - Figure 1. Results of the genotype identification experiment of model mice;

[0029] Fig.10 A diagram of a heat-induced epileptic seizure test device according to the present invention;

[0030] Fig.11 This is a data analysis diagram of the heat-induced epileptic seizure test of the present invention. DETAILED DESCRIPTION

[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium, it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.

[0033] Explanation of terms in this application:

[0034] Cre-loxP system: circular recombinase-crossover (x) P1 site system;

[0035] The mouse genotype background was C57BL / 6J, referred to as C57;

[0036] The mouse genotype background is 129S6 / SvEvTac, referred to as 129;

[0037] Scn1a flox / flox Mouse (100% C57): loxP sites in the same direction were added to both sides of exon 26 of the Scn1a gene of mice with a 100% C57 genotype background, making it a homozygous loxP mouse;

[0038] WildTypeMouse (100% 129): 100% 129 genotype background mice;

[0039] Scn1a flox / + (50% C57 / 50% 129): loxP sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background was 50% C57 / 50% 129;

[0040] WildTypeMouse (25%C57 / 75%129): mice with 25%C57 / 75%129 genotype background;

[0041] Scn1a flox / + (25%C57 / 75%129): loxP sites were added in the same direction on both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background was 25%C57 / 75%129;

[0042] WildTypeMouse (12.5%C57 / 87.5%129): mice with 12.5%C57 / 87.5%129 genotype background;

[0043] Scn1a flox / + (12.5%C57 / 87.5%129): loxP sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background was 12.5%C57 / 87.5%129;

[0044] WildTypeMouse (6.25%C57 / 93.75%129): mice with 6.25%C57 / 93.75%129 genotype background;

[0045] Scn1a flox / +(6.25%C57 / 93.75%129): loxP sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background was 6.25%C57 / 93.75%129;

[0046] Cre + Mouse: mice containing the cyclorecombinase gene, the mouse genotype background is 100% C57;

[0047] Scn1a + / + Mouse (50% C57 / 50% 129): mice containing two copies of the Scn1a gene, with a genotype background of 50% C57 / 50% 129;

[0048] Scn1a + / - Mouse (50% C57 / 50% 129): A mouse containing a single copy of the Scn1a gene, with a genotype background of 50% C57 / 50% 129.

[0049] See also Figure 1-Figure 11 , the present invention provides a technical solution:

[0050] A method for preparing Scn1a using the Cre-loxP system + / - The method of the model mouse comprises the following steps;

[0051] S1: Scn1a with 100% C57 background flox / flox (LoxP sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, resulting in a homozygous loxP mouse) The mouse was hybridized with a wild-type 100% 129 background mouse to obtain an F1 generation with a theoretical background value of 50% C57 / 50% 129 Scn1a flox / + Mice;

[0052] S2: On this basis, the theoretical background value of the F1 generation is 50% C57 / 50% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain an F2 generation with a theoretical background value of 25% C57 / 75% 129 Scn1a flox / + Mice;

[0053] S3: On this basis, the theoretical background value of the F2 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain an F3 generation with a theoretical background value of 12.5% ​​C57 / 87.5% 129 Scn1a flox / + Mice;

[0054] S4: On this basis, the theoretical background value of the F3 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain the F4 generation with a theoretical background value of 6.25% C57 / 93.75% 129 Scn1a flox / + Mice;

[0055] S5:Scn1a flox / + Mice were repeatedly crossed with wild-type 100% 129 mice for ≥3 rounds;

[0056] S6: Scn1a flox / + The mice were repeatedly crossed with wild-type 100% 129 mice. After 3 rounds of crosses, the theoretical background value of the F4 generation was 6.25% C57 / 93.75% 129 Scn1a flox / + The mice were crossed with Cre mice with a 100% C57 background to obtain Scn1a with a background close to 50% C57 / 50% 129 + / - Model mice. 1. Scn1a flox / + and Scn1a flox / flox Mouse genotyping method:

[0057] Experimental principle Figure 6 As shown:

[0058] In the figure:

[0059] Wild Type Mouse (mouse without loxP site, i.e. WT): one band with 271 bp;

[0060] Scn1a flox / + (Mice containing heterozygous loxP sites, i.e. Heterozygous): two bands with 271 and 329 bp;

[0061] Scn1a flox / flox (Mice containing homozygous loxP sites, i.e. Homozygous): one band with 329 bp.

[0062] Reagents:

[0063] (1) Proteinase K manufacturer: Beyotime

[0064] (2) Prepare rat tail buffer:

[0065] 5mL1moL / LTrispH=8.0 146gNaCl

[0066] 5mL1moL / LTrispH=8.0 10mL0.5moL / LEDTApH=8.0

[0067] 25mL10%SDS ddH2Oupto500mL

[0068] (3) ddH2O manufacturer: Beijing Jinshi Quanbiological

[0069] (4), 2XTaqPCRStarMixWithLoadingDye Manufacturer: Genstar

[0070] (5) 50XTAE Manufacturer: Beyotime

[0071] (6) AgaroseRegular Manufacturer: Shenggong

[0072] instrument:

[0073] (1) PCR instrument manufacturer: Eppendorf

[0074] (2) Electrophoresis instrument: Manufacturer: Bio-RAD

[0075] Experimental steps:

[0076] (1) Cage location:

[0077] 10-4-F24 (1-4) 10-4-F116 (5-9, 11-19, 21-22)

[0078] 10-4-E82 (23-24)

[0079] (2) Take 30 μL of Proteinase K solution (1 μL Proteinase K + 29 μL Mouse Tail Buffer) into the ep tube containing the mouse toes and digest at 56°C overnight;

[0080] (3) After overnight digestion of mouse toes, add 100 μL ddH2O to the ep tube and incubate at 100°C for 10 min to inactivate Proteinase K;

[0081] (4) 1200 rpm, 1 min, and the supernatant was used as PCR template;

[0082] (5) PCRReactionComponent

[0083] ForwardPrimer1: CCACCTCCACTCAGCCTTAC

[0084] ReversePrimer1:TCTGCAGCTGATTTGTCCCA

[0085]

[0086] (6) PCR program

[0087]

[0088] (7) Electrophoresis: 2% gel, 120V, 30min

[0089] The experimental results are as follows Figure 7 As shown:

[0090] Experimental conclusion:

[0091] WildTypeMouse: 1, 3, 5, 7, 9, 11, 15, 18, 21, 23

[0092] Scn1a flox / + : 2, 4, 6, 8, 12, 13, 14, 16, 17, 19, 22, 24

[0093] 2. Scn1a + / - Mouse genotype identification method:

[0094] Experimental principle Figure 8 As shown:

[0095] Usually, a small piece of tissue expressing Cre is taken, genomic DNA is extracted, and the flox region is amplified by PCR. The presence or absence of the flox region is used to qualitatively determine whether Cre is working.

[0096]

[0097] Reagents:

[0098] (1) Proteinase K manufacturer: Beyotime

[0099] (2) Prepare rat tail buffer:

[0100] 5mL1moL / LTrispH=8.0 10mL0.5moL / LEDTApH=8.0

[0101] 146gNaCl 5mL1moL / LTrispH=8.0

[0102] 25mL10%SDS ddH2Oupto500mL

[0103] (3) ddH2O manufacturer: Beijing Jinshi Quanbiological

[0104] (4), 2XTaqPCRStarMixWithLoadingDye Manufacturer: Gensta

[0105] (5) 50XTAE Manufacturer: Beyotime

[0106] (6) AgaroseRegular Manufacturer: Shenggong

[0107] instrument:

[0108] (1) PCR instrument manufacturer: Eppendorf

[0109] (2) Electrophoresis instrument manufacturer: Bio-RAD

[0110] Experimental steps:

[0111] (1) Take 30 μL Proteinase K solution (1 μL Proteinase K + 29 μL Mouse Tail Buffer) into the ep tube containing the mouse toes and digest at 56°C overnight;

[0112] (2) After overnight digestion of mouse toes, add 100 μL ddH2O to the ep tube and incubate at 100°C for 10 min to inactivate Proteinase K;

[0113] (3) 1200 rpm, 1 min, and the supernatant was used as PCR template;

[0114] (4) PCRReactionComponent

[0115] ForwardPrimer(P5):TCCACCTCCACTCAGCCTTA

[0116] ReversePrimer(P6):CCCACGATCTAGCGATCACC

[0117]

[0118] (5) PCR program

[0119] (P5andP6)

[0120]

[0121] (6) Electrophoresis: 2% gel, 120V, 30min

[0122] The experimental results are as follows Fig. 9 As shown:

[0123] Experimental conclusion:

[0124] WT(Scn1a + / + ):E554, E555, E556, E557, E560, E561, E562, E563

[0125] Scn1a + / - :E553, E558, E559, E564

[0126] 3. Phenotypic identification: Heat-Induced Seizures Assay

[0127] Experimental principle:

[0128] Mutations in the neuronal voltage-gated sodium channel gene SCN1A most commonly cause Dravet syndrome. Mice with a heterozygous deletion of Scn1a have features of Dravet syndrome, including spontaneous seizures, susceptibility to hyperthermia-induced seizures, and premature lethality.

[0129] Experimental instruments:

[0130] (1) Breathing anesthesia machine manufacturer: Reward

[0131] (2) Infrared lamp heating device manufacturer: Physitemp

[0132] (3) Transparent plastic box (L = 28 cm; D = 28.7 cm; H = 36.7 cm)

[0133] (4) Digital camera manufacturer: Songdian

[0134] (5) Thermometer manufacturer: Deli

[0135] (6) Timer manufacturer: ThermoFisher

[0136] (7) Electronic balance manufacturer: Huazhi Electronics

[0137] (8) Tape manufacturer: Beekman Biotech

[0138] Experimental setup Fig.10 As shown:

[0139] Experimental reagents:

[0140] Isoflurane manufacturer: Yuyan Instruments

[0141] Experimental mice:

[0142] G373-♂-Scn1a + / - -2.7Weeks-9.9g G374-♂-Scn1a+ / - -2.7Weeks-9.4g

[0143] G377-♂-Scn1a + / - -2.7Weeks-8.5g G372-♂-Scn1a + / - -2.7Weeks-10.7g

[0144] G387-♀-Scn1a + / - -3.3Weeks-15.9g G389-♀-Scn1a + / - -3.3Weeks-15.7g

[0145] G370-♂-Scn1a + / + -2.7Weeks-9.1g G371-♂-Scn1a + / + -2.7Weeks-9.4g

[0146] G375-♂-Scn1a + / + -2.7Weeks-8.5g G369-♂-Scn1a + / + -2.8Weeks-9.6g

[0147] G376-♂-Scn1a + / + -2.8Weeks-9.8g G368-♀-Scn1a + / + -2.8Weeks-9.8g G382-♂-Scn1a + / + -3.3Weeks-14.6g G378-♂-Scn1a + / + 3.3Weeks-16.4g Experimental steps:

[0148] (1) The room temperature of the animal room was 21°C;

[0149] (2) Weigh the mice;

[0150] (3) Anesthetize the mice using a respiratory anesthesia machine for 4 minutes;

[0151] (4) Insert the temperature probe into the mouse anus and wrap it around the mouse tail with tape;

[0152] (5) Place the mouse in a transparent plastic box and allow it to adapt for 5 minutes before turning on the infrared lamp for heating;

[0153] (6) The height of the infrared lamp relative to the transparent plastic box is 3 cm (the purpose is to increase the body temperature of the mice by 0.5°C every 2 minutes);

[0154] (7) Use a camera to record mouse activities and temperature changes in real time;

[0155] (8) After the mouse body temperature reached 42.5°C, the infrared lamp heating was stopped and the camera was used to record in real time for another 5 minutes. + / + Mouse and Scn1a + / - The percentage of mice Fig.11 As shown in the figure: (Scn1a + / + Mouse n = 8, Scn1a + / - Mice n=6, p<0.0001)

[0156] Experimental conclusion:

[0157] Heat-induced seizure assays revealed that Scn1a in the F1 generation + / - Scn1a + / + The mice have very obvious phenotypic differences, and the model mice can be used as a disease model for Dravet syndrome.

[0158] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the statement "comprise a ..." do not exclude the presence of other identical elements in the process, method, article or device including the elements.

[0159] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for preparing Scn1a using the Cre-loxP system + / - Model mouse methods, It is characterized in that The steps include: S1: Scn1a with 100% C57 background flox / flox (Loxp sites in the same direction were added to both sides of exon 26 of the mouse Scn1a gene, resulting in mice containing homozygous Loxp) mice were hybridized with wild-type 100% 129 background mice to obtain an F1 generation with a theoretical background value of 50% C57 / 50% 129 Scn1a flox / + Mice; S2: On this basis, the theoretical background value of the F1 generation is 50% C57 / 50% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain an F2 generation with a theoretical background value of 25% C57 / 75% 129 Scn1a flox / + Mice; S3: On this basis, the theoretical background value of the F2 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain an F3 generation with a theoretical background value of 12.5% ​​C57 / 87.5% 129 Scn1a flox / + Mice; S4: On this basis, the theoretical background value of the F3 generation is 25% C57 / 75% 129 Scn1a flox / + The mice were crossed with wild-type 100% 129 mice to obtain the F4 generation with a theoretical background value of 6.25% C57 / 93.75% 129 Scn1a flox / + Mice; S5:Scn1a flox / + Mice were repeatedly crossed with wild-type 100% 129 mice for ≥3 rounds; S6: Scn1a flox / + The mice were repeatedly crossed with wild-type 100% 129 mice. After 3 rounds of crosses, the theoretical background value of the F4 generation was 6.25% C57 / 93.75% 129 Scn1a flox / + The mice were crossed with Cre mice with a 100% C57 background to obtain Scn1a with a background close to 50% C57 / 50% 129 + / - Model mice.

2. The method for preparing Scn1a using the Cre-loxP system according to claim 1 + / - Model mouse methods, Features: The S1 was 100% Scn1a in the C57 background flox / flox The mouse has loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene, and is a mouse containing homozygous loxP.

3. The method for preparing Scn1a using the Cre-loxP system according to claim 1 + / - Model mouse methods, Features: Scn1a in S1 flox / + The (50% C57 / 50% 129) mouse is a mouse containing heterozygous loxP by adding loxP sites in the same direction on both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background is 50% C57 / 50% 129.

4. The method for preparing Scn1a using the Cre-loxP system according to claim 1 + / - Model mouse methods, Features: S3 Scn1a flox / + The (25%C57 / 75%129) mouse is a mouse containing heterozygous loxP by adding loxP sites in the same direction on both sides of exon 26 of the mouse Scn1a gene, and the mouse genotype background is 25%C57 / 75%129.

5. The method for preparing Scn1a using the Cre-loxP system according to claim 1 + / - Model mouse methods, Features: S3 Scn1a flox / + The (12.5%C57 / 87.5%129) mouse is a mouse containing heterozygous loxP with loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene. The mouse genotype background is 12.5%C57 / 87.5%129.

6. The method for preparing Scn1a using the Cre-loxP system according to claim 1 + / - Model mouse methods, Features: Scn1a in S6 flox / + The (6.25%C57 / 93.75%129) mouse is a mouse containing heterozygous loxP with loxP sites in the same direction added to both sides of exon 26 of the mouse Scn1a gene. The mouse genotype background is 6.25%C57 / 93.75%129.

Citation Information

Patent Citations

  • Method for building multi-tissue beta-catenin knockout mouse model

    CN104957094A

  • Construction method for mature adipose tissue beta-catenin knocked-out mouse model

    CN105145470A

  • Pdgfr beta gene specific knockout mouse model as well as construction method and application thereof

    CN116286969A

  • Methods and compositions for translational profiling and molecular phenotyping

    WO2009114185A2